SCHEMBL4548455

SCHEMBL4548455

COC(=O)/C=C/c1ccc(-c2cnn[nH]2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 2/20 0.54
CA1 P00915 2/20 0.54
CA2 P00918 2/20 0.54
CA7 P43166 2/20 0.54
CA9 Q16790 2/20 0.54
CA14 Q9ULX7 2/20 0.54
TYR P14679 1/20 0.54
PTPN1 P18031 1/20 0.48
TTR P02766 1/20 0.47
APP P05067 1/20 0.47
ALOX5 P09917 1/20 0.46
KDM4E B2RXH2 4/20 0.45
MAPT P10636 2/20 0.45
EPHX2 P34913 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
KMT2A Q03164 2/20 0.43
ALDH1A1 P00352 2/20 0.43
JAK2 O60674 1/20 0.43
GAA P10253 1/20 0.43
HTT P42858 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4548451 0.82 ESR1 (0.49) CA12CA1CA2CA7CA9
SCHEMBL71224 0.78 CA12 (0.84) CA12CA1CA2CA7CA9
SCHEMBL5057418 0.78 CA12 (0.84) CA12CA1CA2CA7CA9
SCHEMBL28320610 0.76 MAPT (0.51) TTRALOX5KDM4EMAPTSMN1; SMN2
SCHEMBL404484 0.73 CA12 (0.89) CA12CA1CA2CA7CA9
SCHEMBL4833224 0.73 CA12 (0.66) CA12CA1CA2CA7CA9
SCHEMBL4833218 0.73 CA12 (0.66) CA12CA1CA2CA7CA9
SCHEMBL404485 0.73 CA12 (0.89) CA12CA1CA2CA7CA9
SCHEMBL8267192 0.72 HDAC8 (0.73) CA12CA1CA2CA7CA9
SCHEMBL1842884 0.72 CA12 (0.64) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120178750-A1 Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment MERCK SHARP & DOHME CORP. (US) 2012-07-12 US disclosed
US-20120178750-A1 Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment MERCK SHARP & DOHME CORP. (US) 2012-07-12 US disclosed
US-8168649-B2 Niacin receptor agonists, compositions containing such compounds and methods of treatment Merk Sharp & Dohme Corp. (US) 2012-05-01 US disclosed
US-8168649-B2 Niacin receptor agonists, compositions containing such compounds and methods of treatment Merk Sharp & Dohme Corp. (US) 2012-05-01 US disclosed
US-20100144778-A1 Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment MERCK SHARP & DOHME LLC 2010-06-10 US disclosed
US-20100144778-A1 Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment MERCK SHARP & DOHME LLC 2010-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144778-A1 Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment HCAR1, HCAR2, GPR119 CA12 4033/4885CA1 3927/4885CA2 2687/4885
US-20120178750-A1 Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment HCAR1, HCAR2, FFAR1 CA12 4054/4885CA1 3956/4885CA2 2751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.